KOSPIBiotech & Pharma271980

Jeil Pharmaceutical

₩8,390▼ 2.21%2026-11-18 close
Market Cap
₩123.4B
Turnover
₩100M
Volume
20K
Shares out.
14.7M
PER
—
PBR
0.6×
EPS
-₩445
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Own-brand growth, but two straight quarters of operating losses

Own-brand sales led by Jaqbo are growing, but higher R&D and SG&A costs have kept Jeil Pharmaceutical in operating losses for the second and third quarters of 2026.

  1. 1

    Operating profit for 2025 was KRW 20.7 billion, a return to profit, but operating losses followed in the second and third quarters of 2026.

  2. 2

    Product sales rose 13% year on year in the third quarter of 2026, and Jaqbo sales grew 36.4% to KRW 25.9 billion, but revenue gains did not keep pace with cost increases.

  3. 3

    Third-quarter 2026 SG&A rose 30.5% to KRW 58.4 billion and recurring R&D expenses rose 73% to KRW 16.6 billion, pressuring the profit structure.

  4. 4

    Jaqbo has technology export and supply agreements in 27 countries, and the diabetes candidate JP-2266 is preparing to enter Phase 3 clinical trials.

  5. 5

    Net loss attributable to controlling shareholders has continued for three straight quarters from the first quarter of 2026 through the third quarter, with a combined loss of KRW 6.6 billion over the last four quarters.

02

Business structure

Jeil Pharmaceutical's sales fall into two groups: its own products (product sales) and products it sources from outside partners for resale (merchandise sales). Third-quarter 2026 product sales were KRW 69.6 billion, up 13% (KRW 8.0 billion) from KRW 61.6 billion a year earlier.

Merchandise sales in the same quarter were KRW 65.3 billion, down 0.8% (KRW 0.5 billion) from KRW 65.8 billion, as Lipitor sales rose 2.8% to KRW 36.8 billion but could not offset the overall decline.

Among products, the gastroesophageal reflux drug Jaqbo reached KRW 25.9 billion, up 36.4%, and Lipitor Plus reached KRW 6.6 billion, up 83.3%. Reports put the share of own products in sales at 42.4% as of the third quarter of 2025, up from 29.1% a year earlier.

Jaqbo was developed by the company's R&D subsidiary, and technology export or supply agreements have been signed in 27 countries including China, India, Latin America and Northern Europe.

In August 2026, India's Central Drugs Standard Control Organization approved it for erosive gastroesophageal reflux disease, the first overseas marketing approval for the drug.

Pipeline assets include the type 2 diabetes candidate JP-2266, which dual-inhibits SGLT1 and SGLT2 and has completed Phase 2, and the anticancer candidate JP9441, which is at an early development stage.

Lipitor Plus was co-launched with Viatris, with Jeil Pharmaceutical producing the finished product from Viatris-supplied ingredients and the two companies co-marketing it.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩134.8B₩9.8B7.3%
2025Q4₩131.8B₩500M0.4%
2026Q1₩130.3B₩400M0.3%
2026Q2₩146.6B-₩7B−4.8%
2026Q3₩136.7B-₩6.3B−4.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩722.2B-₩13.5B-₩13.1B−1.9%−8.3%193.6%
2023₩726.4B₩8.7B₩5B1.2%3.2%210.3%
2024₩704.5B-₩18.9B-₩30B−2.7%−15.9%139.7%
2025₩567.2B₩20.7B₩23.4B3.6%11.1%103.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual sales went from KRW 722.2 billion in 2022 to KRW 726.4 billion in 2023 (up 0.6% year on year), the peak of the period. Sales then fell to KRW 704.5 billion in 2024 (down 3.0%) and KRW 567.2 billion in 2025 (down 19.5%), a two-year decline from 2024 through 2025.

Within 2022–2025, 2023 was the largest year and 2025 the smallest.

Operating results moved from an operating loss of KRW 13.5 billion in 2022 to operating profit of KRW 8.73 billion in 2023, a turn to profit, then to an operating loss of KRW 18.9 billion in 2024, a turn to loss, and back to operating profit of KRW 20.7 billion in 2025, a turn to profit.

The operating margin improved from -1.9% in 2022 to 1.2% in 2023, -2.7% in 2024 and 3.6% in 2025. Net profit attributable to controlling shareholders was KRW 5 billion in 2023 and KRW 23.4 billion in 2025, while 2022 and 2024 posted losses of KRW 13.1 billion and KRW 30 billion.

Net profit including non-controlling interests is a different figure, at KRW 32 billion for 2025. Industry reports cited the loss of some in-licensed products as a factor behind the 2025 sales decline.

The debt-to-equity ratio fell from 193.6% in 2022 and 210.3% in 2023 to 139.7% in 2024 and 103.4% in 2025, with total equity at KRW 251 billion at the end of 2025, of which KRW 211.1 billion was attributable to controlling shareholders, and total liabilities at KRW 259.5 billion.

Operating cash flow was positive at KRW 3.21 billion in 2024 but negative at -KRW 5.69 billion in 2025. By quarter, operating profit of KRW 9.82 billion in the third quarter of 2025 was followed by KRW 534 million in the fourth quarter, down 94.6% from the prior quarter.

Operating profit was KRW 418 million in the first quarter of 2026, followed by an operating loss of KRW 7.04 billion in the second quarter, a turn to loss, and an operating loss of KRW 6.25 billion in the third quarter, making two consecutive loss-making quarters from the second through the third quarter of 2026.

Third-quarter 2026 sales were KRW 136.7 billion, up 1.4% year on year, but gross profit fell 4.4% to KRW 52.1 billion and SG&A rose 30.5% to KRW 58.4 billion, according to reporting on that quarter.

The same reporting put recurring R&D expenses at KRW 16.6 billion, up 73%, and the company attributed the profitability decline mainly to higher R&D spending.

Net loss attributable to controlling shareholders was KRW 310 million in the first quarter of 2026, KRW 8.02 billion in the second and KRW 5.64 billion in the third, three straight loss quarters with a combined KRW 6.6 billion loss over the last four quarters.

05

Industry analysis

Profitability at Korean traditional pharmaceutical companies is strongly shaped by the drug pricing environment. According to Dailypharm, 62 traditional pharma companies saw third-quarter 2026 operating profit fall 7%, and more than half recorded either a drop in operating profit or an operating loss.

Weakness was especially pronounced among smaller companies with modest revenue. Companies centered on non-reimbursed and global businesses performed relatively better.

The same report said concern about profitability is rising among reimbursement-dependent traditional pharma firms ahead of the price cuts on existing reimbursed drugs scheduled for 2027.

Jeil Pharmaceutical's merchandise sales of KRW 65.3 billion in the third quarter of 2026 were close in size to its product sales of KRW 69.6 billion, so it is exposed to the pricing environment for reimbursed and in-licensed products.

On the own-brand side, Jaqbo is widening the business model through more overseas approvals and agreements. The company overhauled the structure of its central research institute and brought in outside experts to strengthen its research capabilities.

The government's K-VIP program also supports pharma and bio companies expanding overseas in response to export-control and supply-chain risks.

Within the domestic pharma sector, the competitive divide appears to be between companies whose pipelines deliver technology-export results and those dependent on reimbursed product margins.

06

Outlook

The company has made technology exports and overseas partnering the core priority for its proprietary pipeline. Under its participation plan for BIO-Europe 2026, announced on November 9, 2026, it presented JP-2266, JP9441 and Duglow as key partnering assets and planned to discuss technology exports and co-development.

JP-2266 confirmed reductions in HbA1c, fasting and postprandial glucose and safety in Phase 2, and is preparing to enter Phase 3. The company aims to submit an Investigational New Drug application for a Phase 3 trial in Korea within 2026 and is refining its late-stage trial design and approval strategy.

JP9441 is an SOS1 inhibitor-based candidate for solid tumors with KRAS mutations, and is reportedly preparing to enter a Phase 1 trial in Korea. Jaqbo's Chinese partner Livzon is undergoing marketing approval review and running a Phase 3 study of an injectable form and of an H. pylori eradication regimen.

To expand Jaqbo production, the company invested KRW 24.9 billion in expanding the Baegam plant in Yongin, Gyeonggi Province. In October 2026, it was selected by the Korea Health Industry Development Institute for the K-VIP program, which funds costs of attending overseas conferences and partnering events.

The reorganization of the central research institute and the hiring of outside experts tie into plans to broaden next-generation innovative drug research around cancer and age-related complex diseases.

The next checkpoint is whether the annual operating margin and the quarterly loss trend are confirmed in the 2026 annual report, the next periodic filing.

07

Valuation

PER
—
PBR
0.6×
ROE
-3.3%
EPS
-₩445
BPS
₩13,635
Dividend per share
₩0

The price-to-book ratio is below 1x, meaning the stock trades at a low multiple of book value. Because net loss attributable to controlling shareholders totaled KRW 6.6 billion over the last four quarters, a price-to-earnings multiple based on that period cannot be calculated.

Net profit attributable to controlling shareholders turned positive at KRW 23.4 billion in 2025, but quarterly losses have continued through 2026. The dividend yield is low, so the share price is hard to explain through dividends.

The debt-to-equity ratio fell from 193.6% in 2022 to 103.4% in 2025, a direction of easing balance-sheet pressure. A low multiple of net assets should be read alongside whether earnings power recovers.

How the valuation is read depends on the progress of the proprietary pipeline in clinical trials and on when quarterly operating profit recovers.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Double-digit product sales growth

Third-quarter 2026 product sales rose 13% year on year to KRW 69.6 billion, and Jaqbo sales grew 36.4% to KRW 25.9 billion. Consolidated Jaqbo sales in the first half of 2026 reached KRW 64.5 billion, up about 152% from a year earlier. The growing share of own products is the basis for the shift in the earnings structure.

Overseas licensing and supply agreements

Jaqbo has technology export and supply agreements in 27 countries, including China, India, Latin America and Northern Europe. It received its first overseas marketing approval in India in August 2026, and its Chinese partner is undergoing approval review. Whether these overseas agreements translate into actual sales is the next point to monitor.

Progress of the JP-2266 clinical program

JP-2266, an oral candidate that simultaneously inhibits SGLT1 and SGLT2, has completed Phase 2. The achievement rate for reaching an HbA1c target below 7% was up to 70.6%. The company aims to submit a Phase 3 trial plan in Korea within 2026.

09

Bear factors

Two consecutive quarters of operating losses

Operating losses of KRW 7.04 billion in the second quarter and KRW 6.25 billion in the third quarter of 2026 mark two consecutive loss quarters. Recurring R&D expenses rose 73% to KRW 16.6 billion and SG&A rose 30.5% to KRW 58.4 billion in the third quarter of 2026. Even with higher sales, rising costs are limiting the recovery in profit.

Merchandise sales decline and shrinking annual revenue

Third-quarter 2026 merchandise sales fell 0.8% year on year to KRW 65.3 billion. Annual sales declined two years in a row, to KRW 704.5 billion in 2024 and KRW 567.2 billion in 2025, a 19.5% drop in 2025. Industry reports cited the loss of some in-licensed products as a factor behind the revenue decline.

Pricing pressure on the sector

According to Dailypharm, operating profit at 62 traditional pharma companies fell 7% in the third quarter of 2026. Concern is growing over the profitability of reimbursement-focused companies ahead of the price cuts on existing reimbursed drugs scheduled for 2027.

Jeil Pharmaceutical's merchandise sales could also be affected by the pricing environment for reimbursed and in-licensed products.

10

Risk factors

Clinical and pipeline risk

JP-2266 is preparing to enter Phase 3, while JP9441 is at an early development stage. If clinical results fall short of expectations, the valuation of the pipeline may need to be reassessed. It is also uncertain whether technology export agreements will translate into actual royalties and milestone payments. If R&D spending continues to rise, the period of losses could extend.

Financial structure risk

Total liabilities at the end of 2025 were KRW 259.5 billion, with a debt-to-equity ratio of 103.4%. Operating cash flow was negative at -KRW 5.69 billion in 2025.

Net losses attributable to controlling shareholders have continued from the first quarter through the third quarter of 2026, so the trend in capital headroom needs to be monitored.

Overseas approval and policy risk

Jaqbo's approval in China is at the review stage with the local partner, and the timing has not been set. Even with the approval in India, the scale of overseas sales remains limited. Export controls and supply-chain changes could affect the pace at which overseas supply agreements are carried out.

11

What to watch next

  1. By late December 2026

    Whether the Phase 3 IND for JP-2266 is submitted in Korea. The company targets submission within 2026, making it the first formal checkpoint on pipeline progress.

  2. End of March 2027

    Filing of the 2026 annual report. It will confirm the annual operating margin and the operating loss trend since the second quarter of 2026 on a full-year basis.

  3. Mid-May 2027

    First-quarter 2027 quarterly report. It will show whether the operating losses that continued through the third quarter of 2026 are reversing.

  4. 2027 (effective date to be confirmed)

    Implementation of the price cuts on existing reimbursed drugs and their impact on reimbursed and in-licensed products. This is a variable for gauging the direction of the traditional pharma sector and Jeil Pharmaceutical's merchandise sales.

12

Overall view

Jeil Pharmaceutical's product sales are growing at a double-digit pace led by Jaqbo, and the company is presenting Jaqbo's overseas agreements and JP-2266's clinical progress as the pillars of medium-term growth.

However, despite returning to annual profit in 2025, operating losses continued in the second and third quarters of 2026, and SG&A and R&D expenses rose faster than revenue. Merchandise sales declined, and pricing pressure ahead of the 2027 price cuts is being discussed across the sector.

On the financial side, the debt-to-equity ratio fell from 193.6% in 2022 to 103.4% in 2025, but a combined net loss attributable to controlling shareholders of KRW 6.6 billion over the last four quarters remains.

Strengths include own-product growth and pipeline progress, while weaknesses include the cost structure, falling merchandise sales and the pricing environment. The next checkpoints are the JP-2266 Phase 3 IND submission within 2026 and the annual operating margin in the 2026 annual report. This report is provided for information only and does not constitute an investment opinion.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. view.asiae.co.kr
  2. fnnews.com
  3. vegannews.co.kr
  4. econovill.com
  5. kpenews.com
  6. m.sedaily.com
  7. newspost.kr
  8. consumernews.co.kr
  9. bosa.co.kr
  10. dealsite.co.kr
  11. dailian.co.kr
  12. thebionews.net
  13. daily.hankooki.com
  14. seo.goover.ai
  15. dailypharm.com
  16. m.dailypharm.com
  17. pharm.edaily.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis